Literature DB >> 29355969

Primary liver sarcomas in the modern era: Resection or transplantation?

Ioannis T Konstantinidis1, Carolijn Nota1, Zeljka Jutric1, Philip Ituarte2, Warren Chow3, Peiguo Chu4, Gagandeep Singh1, Susanne G Warner1, Laleh G Melstrom1, Yuman Fong1.   

Abstract

BACKGROUND AND OBJECTIVES: Primary liver sarcomas (PLS) are rare. Published series are limited by small numbers of patients.
METHODS: We reviewed the National Cancer Database (2004-2014) for patients who underwent surgical resection of PLS.
RESULTS: Of 237 patients identified, the majority were female (60.8%), with median age of 52 years. Histologies were: epithelioid hemangioendothelioma (n = 67), angiosarcoma (n = 64), leiomyosarcoma (n = 33), embryonal rhabdomyosarcoma (n = 31), carcinosarcoma (n = 16), giant cell sarcoma (n = 14), spindle cell sarcoma (n = 12). Ninety-seven (40.9%) patients underwent lobectomies or extended lobectomies, 41 patients (17.3%) underwent transplantation. Surgical margins were negative in 82.9%. Tumors were well differentiated in 11.3%. Histology type correlated with outcome with the best prognosis for epithelioid hemangioendothelioma (OS: not reached, similar for resection and transplantation) and the worst for angiosarcoma (OS:16.6 mo with resection; 6 mo with transplantation; P = 0.04). Resections with microscopically negative margins were associated with improved survival (58.7 vs 11.3 mo for positive margins; P < 0.001). Chemotherapy and radiation therapy were used in a minority of patients (32.9% and 4.3% respectively) with no improvement in outcomes.
CONCLUSIONS: Both hepatic resection and liver transplantation can be associated with long term survival for selected primary liver sarcomas such as epitheliod hemangioendotheliomas. Histology type and the ability to resect the tumor with negative margins correlate with outcomes and the decision to operate should be carefully weighed for subtypes with particularly dismal prognosis such as angiosarcomas.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  primary liver sarcomas; resection; transplantation

Mesh:

Year:  2018        PMID: 29355969      PMCID: PMC5992101          DOI: 10.1002/jso.24979

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  11 in total

1.  Surgical treatment of adult primary hepatic sarcoma.

Authors:  J L Poggio; D M Nagorney; A G Nascimento; C Rowland; P Kay; R M Young; J H Donohue
Journal:  Br J Surg       Date:  2000-11       Impact factor: 6.939

2.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

Review 3.  Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy.

Authors:  Arianeb Mehrabi; Arash Kashfi; Hamidreza Fonouni; Peter Schemmer; Bruno M Schmied; Peter Hallscheidt; Peter Schirmacher; Jurgen Weitz; Helmut Friess; Markus W Buchler; Jan Schmidt
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

4.  Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment.

Authors: 
Journal:  Ann Surg       Date:  1990-03       Impact factor: 12.969

5.  Management of primary liver sarcomas.

Authors:  Juürgen Weitz; David S Klimstra; Karina Cymes; William R Jarnagin; Michael D'Angelica; Michael P La Quaglia; Yuman Fong; Murray F Brennan; Leslie H Blumgart; Ronald P Dematteo
Journal:  Cancer       Date:  2007-04-01       Impact factor: 6.860

6.  Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma.

Authors:  H R Kim; S Y Rha; S H Cheon; J K Roh; Y N Park; N C Yoo
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

7.  The national cancer data base: past, present, and future.

Authors:  David P Winchester; Andrew K Stewart; Jerri Linn Phillips; Elizabeth E Ward
Journal:  Ann Surg Oncol       Date:  2009-10-22       Impact factor: 5.344

8.  Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation--the European Liver Transplant Registry experience.

Authors:  Giuseppe Orlando; Rene Adam; Darius Mirza; Goran Soderdahl; Robert J Porte; Andreas Paul; Andrew K Burroughs; Christian A Seiler; Michele Colledan; Ivo Graziadei; Juan-Carlos Garcia Valdecasas; François-René Pruvot; Vincent Karam; Jan Lerut
Journal:  Transplantation       Date:  2013-03-27       Impact factor: 4.939

9.  Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base.

Authors:  Karl Y Bilimoria; David J Bentrem; Andrew K Stewart; David P Winchester; Clifford Y Ko
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

10.  The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry.

Authors:  Jan P Lerut; Giuseppe Orlando; Rene Adam; Marcello Schiavo; Jurgen Klempnauer; Darius Mirza; Emmanuel Boleslawski; Andrew Burroughs; Carlos Fernandez Sellés; Daniel Jaeck; Robert Pfitzmann; Mauro Salizzoni; Gunner Söderdahl; Rudi Steininger; Andre Wettergren; Vincenzo Mazzaferro; Yves Patrice Le Treut; Vincent Karam
Journal:  Ann Surg       Date:  2007-12       Impact factor: 12.969

View more
  10 in total

Review 1.  Liver Transplant Oncology: Towards Dynamic Tumor-Biology-Oriented Patient Selection.

Authors:  Matthias Ilmer; Markus Otto Guba
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

2.  Treatment Outcomes for Primary Hepatic Angiosarcoma: National Cancer Database Analysis 2004-2014.

Authors:  Ankit Mangla; Gino Cioffi; Jill S Barnholtz-Sloan; Richard T Lee
Journal:  Curr Oncol       Date:  2022-05-17       Impact factor: 3.109

Review 3.  Recent advances in liver transplantation for cancer: The future of transplant oncology.

Authors:  Phillipe Abreu; Andre Gorgen; Graziano Oldani; Taizo Hibi; Gonzalo Sapisochin
Journal:  JHEP Rep       Date:  2019-07-30

4.  Initial clinical radiological findings and staging to predict prognosis of primary hepatic angiosarcoma: A retrospective analysis.

Authors:  Wei-Hsin Yuan; Anna Fen-Yau Li; Hui-Chen Hsu; Yong-Sin Hu; Rheun-Chuan Lee
Journal:  PLoS One       Date:  2019-11-11       Impact factor: 3.240

5.  Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?

Authors:  Anastasios Kyriazoglou; Konstantinos Koutsoukos; Flora Zagouri; Michalis Liontos; Efthimios Dimitriadis; Dina Tiniakos; Meletios Athanasios Dimopoulos
Journal:  Ther Clin Risk Manag       Date:  2020-02-27       Impact factor: 2.423

6.  Cancer registry study of malignant hepatic vascular tumors: hepatic angiosarcomas and hepatic epithelioid hemangioendotheliomas.

Authors:  Constanza Martínez; Jonathan K Lai; Daryl Ramai; Antonio Facciorusso; Zu-Hua Gao
Journal:  Cancer Med       Date:  2021-12-01       Impact factor: 4.452

7.  Rare Malignant Indications for Liver Transplantation: A Collaborative Transplant Study Report.

Authors:  Philipp Houben; Simon Schimmack; Christian Unterrainer; Bernd Döhler; Arianeb Mehrabi; Caner Süsal
Journal:  Front Surg       Date:  2021-12-03

8.  Establishment and Validation of a Nomogram Prognostic Model for Epithelioid Hemangioendothelioma.

Authors:  Yujun Li; Zibo Zhang; Chunxia Zhang; Jia Li; Bin Zhang; Yan Dong; Xiaonan Cui
Journal:  J Oncol       Date:  2022-10-06       Impact factor: 4.501

9.  Surgical treatment outcomes of primary hepatic sarcomas: A single-center experience.

Authors:  Sang Jin Kim; Jinsoo Rhu; Jong Man Kim; Gyu Seung Choi; Jae-Won Joh
Journal:  World J Hepatol       Date:  2021-05-27

10.  Hepatectomy for Breast Cancer Metastasis and Sarcoma are more likely to have Adverse Outcomes than Hepatectomy for Primary Hepatocellular Cancer or for Colorectal Metastasis.

Authors:  Hassan Aziz; Kamil Hanna; Muhammad Wasif Saif; Muhammad Ameen Rauf; Yuri Genyk; Mohd Raashid Sheikh
Journal:  Cancer Med J       Date:  2020-07-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.